Serodiagnostic Potential of *Mycobacterium avium* MAV2054 and MAV5183 Proteins

A-Rum Shin,a Kil-Soo Lee,a Kang In Lee,a Tae Sun Shim,a Won-Jung Koh,a Haet Sal Jeon,a Yeo-Jin Son,a Sung-Jae Shin,a Hwa-Jung Kim,a

Department of Microbiology and Research Institute for Medical Sciences, Infection Signaling Network Research Center, College of Medicine, Chungnam National University, Daejeon, South Korea; Department of Bacterial Respiratory Infections, Center for Infectious Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention, Seoul, South Korea; Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Microbiology and Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, South Korea

The *Mycobacterium avium*-M. *intracellulare* complex (MAC) causes a pulmonary disease (PD) similar to tuberculosis (TB). Diagnosis of MAC-PD is complicated and time-consuming. In this study, the serodiagnostic potential of the newly identified MAV2054 and MAV5183 proteins was evaluated in subjects with MAC-PD, pulmonary TB, or latent TB and in noninfected healthy controls (HC), together with HspX and the 38-kDa antigen, well-known serodiagnostic *M. tuberculosis* antigens. All four antigens evoked significantly higher IgG responses in MAC-PD and active TB than in latent TB and HC subjects. Among the antigens, MAV2054 elicited the highest antibody responses in pulmonary TB and MAC-PD patients. IgG titers against MAV2054 and MAV5183 were significantly higher in MAC-PD than in pulmonary TB subjects. In addition, the levels of IgG against all antigens in the *M. intracellulare* and fibrocavitary forms were higher than those in the *M. avium* and nodular bronchiectatic forms, respectively. Based on sensitivity and receiver operator characteristic curve analysis, the best candidates for detection of MAC-PD and pulmonary TB were MAV2054 and the 38-kDa antigen, respectively. In total, 76.0% of MAC-PD and 65.0% of active TB patients were reactive to at least two antigens. In contrast, only 2.8% of HC subjects were reactive with two or more antigens. Our findings suggest that an enzyme-linked immunosorbent assay (ELISA) using the four antigens would be valuable for screening for mycobacterial lung disease, including MAC-PD and pulmonary TB, although it does not provide good discrimination of the disease-causing pathogens.

More than 100 species are recognized in the genus *Mycobacterium*, and other than the two well-known mycobacterial species *Mycobacterium tuberculosis* and *M. leprae*, most are ubiquitous in the environment in soil, dust, plants, natural waters, food, and biofilms (1–3). These mycobacteria, previously known as atypical mycobacteria, are now more commonly called nontuberculous mycobacteria (NTM). The pathogens most commonly associated with NTM disease are the *M. avium* complex (MAC), *M. abscessus*, and *M. kansasii* (4). NTM can cause chronic pulmonary disease (PD) in humans similar to slowly progressive pulmonary tuberculosis (TB), but unlike tuberculosis, infection by NTM is not transmitted from person to person. Currently, the diagnosis of NTM-PD remains a challenge due to the complex diagnostic criteria, and the management of NTM-PD is difficult due to the prolonged treatment duration and resistance to antitubercular drugs (5).

MAC is the most common cause of NTM lung diseases and is an opportunistic infectious agent encountered frequently in patients who are immunocompromised, such as individuals with human immunodeficiency virus (HIV) infection (6). Furthermore, the prevalence of MAC-PD in immunocompetent patients has increased recently (5). The diagnosis of MAC-PD is complicated and time-consuming, because MAC may colonize the respiratory tract, and the isolation of MAC from sputum specimens often has no clinical or microbiologic significance due to its ubiquity in nature. In addition, discrimination of MAC-PD from pulmonary TB is difficult. Although the American Thoracic Society (ATS) has outlined guidelines for the diagnosis of NTM, the diagnosis of MAC-PD requires combined clinical, radiographic, and microbiologic evidence (5). Therefore, there have been many efforts to overcome these difficulties in diagnosis of MAC-PD.

There have been few attempts to develop a serologic test for diagnosis of MAC-PD and to distinguish it from other lung diseases, such as TB (7). Serodiagnostic tests using multiple mycobacterial antigens (Ag) are attractive for diagnosis of the disease due to their simplicity and economics. Use of glycopeptidolipids (GPLs) as markers for differentiation of MAC-PD from pulmonary TB and other mycobacterial infections has been reported (8–11). However, mycobacterial glycolipids, such as GPL and cord factor, are difficult to purify in quantity, and their preparation requires great labor and is associated with a high cost. *M. avium* KatG is the only protein reported as a novel diagnostic marker of *M. avium* infection (12). Therefore, identification of seroreactive proteins from MAC culture filtrate and evaluation of their usefulness to distinguish MAC-PD from pulmonary TB or healthy controls (HC) still need to be investigated more extensively.
We previously reported the serodiagnostic potential of a mycobacterial antigen cocktail for detection of TB using an enzyme-linked immunosorbent assay (ELISA) (13). In the present study, to apply the combined ELISA for serologic diagnosis of MAC-PD, we identified two candidates, MAV2054 and MAV5183, by screening using multidimensional fractionation of *M. avium* culture filtrate proteins (CFP) and probing with sera from patients with MAC-PD. In addition, HspX and 38-kDa protein (PstS1), well-known serodiagnostic *M. tuberculosis* antigens, were included in the antibody detection assay. The serodiagnostic potential of all four antigens was evaluated in subjects with MAC-PD, pulmonary TB, or latent TB and in HC. MAV2054 and MAV5183 proteins elicited significantly higher antibody responses in MAC-PD than in pulmonary TB and HC subjects.

**MATERIALS AND METHODS**

**Subjects.** Sera were obtained from 175 patients with MAC-PD (median age = 60 years; age range = 27 to 85 years; percentage of males, 38%), 123 with active pulmonary TB (median age = 52 years; age range = 18 to 91 years; percentage of males, 63%), 151 with latent TB infection (LTBI) as defined by positive tuberculin skin test (TST) results (median age = 22 years; age range = 14 to 63 years; percentage of males, 54%), and 141 HC as defined by negative TST results (median age = 23 years; age range = 8 to 69 years; percentage of males, 62%). A total of 175 MAC patients who satisfied the diagnostic criteria of the American Thoracic Society (ATS) (5) were prospectively enrolled at the Asan Medical Center (Seoul, South Korea) or Samsung Medical Center (Seoul, South Korea). All serum samples obtained from MAC-PD patients from the two hospitals were accompanied by information about the isolated disease-causing bacteria (*M. avium* or *M. intracellulare*), while some included more-detailed information regarding TST results or diagnosis of one of two distinct subtypes, the nodular bronchiectatic form or fibrocavitary form, on the basis of radiographic features as identified by chest computed tomography.

Sera were obtained from patients with active TB or MAC-PD either before or during the first 2 weeks of medication. A basic diagnosis of TB was determined by acid-fast bacillus (AFB) staining and culture results as well as clinical evaluation, such as chest X-ray. Of 123 pulmonary TB sera, 97 were smear or culture positive and 26 were smear and culture negative. Colonies were identified as *M. tuberculosis* or *M. avium* complex using the AccuProbe test (Gen-Probe Inc., San Diego, CA) or a duplex PCR kit (M&D, Wonju, South Korea). MAC species were identified using a PCR-restriction fragment length polymorphism method, based on the *rpoB* gene (14).

Serum samples from LTBI patients were selected from the healthy participants from the Asan Medical Center based on TST results, including or not including a history of previous TB disease or exposure to risk factors for TB. TSTs were performed using 2 tuberculin units (TU) of PPD RT23 (Statens Serum Institute, Copenhagen, Denmark) and the Mantoux method (15), and induration size was measured after 48 to 72 h using the ballpoint method. An induration diameter of more than 10 mm was regarded as a positive result, and consequently, sera from a total of 151 individuals with positive TST results and 141 HC with negative TST results and no history of clinical TB were collected. In addition, an gamma interferon release assay (IGRA) in some subjects with MAC-PD or LTBI and in HC was performed using QuantiFERON-TB Gold (QFT-G; Cellestis Ltd., Carnegie, Victoria, Australia) (16). All serum samples were collected after written consent had been provided by participants, and the study protocol was approved by the Institutional Review Board (IRB) of the Asan Medical and Samsung Medical Centers.

**Multidimensional fractionation of CFP.** The *M. avium* 104 strain was grown for 6 weeks at 37°C as surface pellicles on Sauton’s medium as described previously (17, 18). Culture filtrate proteins (CFP) were filter sterilized and concentrated by ultrafiltration (Amicon Ultra centrifugal filter unit with 3-kDa molecular mass cutoff; Millipore, Bedford, MA). Multidimensional fractionation was performed as described previously (19). In brief, the CFP was precipitated with ammonium sulfate (50% and 80% saturation). The resulting precipitates were dissolved in 50 mM potassium phosphate buffer (PB) containing 1 M ammonium sulfate, and then were separated by hydrophobic interaction chromatography (HIC) using phenyl Sepharose (GE Healthcare Biosciences, Piscataway, NJ) with a linear decreasing gradient of 1 to 0 M ammonium sulfate–50 mM PB and further eluted with 1 mM PB. Each eluate fraction was divided into three subfractions according to its major band pattern upon resolution by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Each of the primary fractions was concentrated separately, dialyzed against 1 mM PB, and then was further fractionated by hydroxyapatite chromatography with elution using a gradient of 1 to 300 mM PB. The eluate was pooled into individual subfractions according to its protein band pattern and concentrated. A third fractionation step was performed using diethylaminoethanol (DEAE) ion-exchange chromatography and a linear salt gradient of 0 to 300 mM NaCl–20 mM Tris-HCl (pH 8.0). All pooled fractions were concentrated and stored at −70°C until use.

**Protein identification.** The major bands of the different fractions that strongly reacted with sera from patients with MAC-PD were selected and subjected to liquid chromatography–electrospray ionization–mass spectrometry (LC–ESI–MS) at the Yonsei Proteomics Research Center (Yonsei University, Seoul, South Korea) as described previously (13, 17).

**Preparation of recombinant proteins.** For this study, four recombinant antigens, the newly identified MAC proteins, MAV2054 and MAV5183, and the well-characterized *M. tuberculosis* proteins HspX and 38-kDa, were prepared. The HspX and 38-kDa proteins were produced in *Escherichia coli* and purified as described previously (13).

To produce MAV2054 and MAV5183, the corresponding genes were amplified by PCR using *M. avium* 104 genomic DNA as the template and the following primers: MAV2054-forward, 5′-CATATGACGTCGGCTC AAAATGAGCTC-3′; MAV2054-reverse, 5′-AAGCTTCCTGGTATCCTAT C GAACTGATC-3′; MAV5183-forward, 5′-GATATGCACAACGGCG GCCTCCGGTG-3′; and MAV5183-reverse, 5′-AAGCTTTGTTGGCGG CTGGGCAGTTG-3′. Using the Signal P 4.0 server (http://www.cbs.dtu. dk/services/SignalP), which predicts the presence and location of N-terminal signal peptide cleavage sites within amino acid sequences, MAV5183 was determined to be a secretory protein with a putative signal sequence. Therefore, MAV5183 was amplified by PCR without the forward primer, which covered the sequence for secretion. Each PCR product was cut with NdeI and HindIII and then inserted into the pET22b (+) vector (Novagen, Madison, WI). The recombinant proteins were overexpressed in *E. coli* BL21 cells carrying bacteriophage DE3 and were purified by nickel-nitrioltriacetic acid (Ni-NTA) affinity chromatography in accordance with the manufacturer’s instructions (Qiagen, Chatsworth, CA). The purified protein was pooled, concentrated, and dialyzed against phosphate-buffered saline (PBS; pH 7.4). Lastly, purified recombinant proteins were filter sterilized and stored at −70°C. Protein concentration was estimated using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL) with bovine serum albumin (BSA) as the standard.

**ELISA.** An enzyme-linked immunosorbent assay (ELISA) was performed as described previously (20). Briefly, the recombinant antigens (1 μg/ml) were diluted in a coating buffer (KPL, Inc., Gaithersburg, MD), and 100 μl was added to each well in 96-well microtiter plates (Maxisorp; Nalge Nunc International, Rochester, NY). After overnight incubation at 4°C, the plates were washed three times with 1 × washing buffer (KPL, Inc.), and then the wells were blocked with 5% BSA–PBS at room temperature for 3 h. After three more washes, 100 μl/well human serum (1:200 dilution) was added to each plate, and the plates were incubated at room temperature for 1 h. After washing, 100 μl of peroxidase-conjugated goat anti-human IgG (Sigma-Aldrich, St. Louis, MO) at a 1:6,000 dilution was added to each well. The plates were then incubated for an additional 30 min at room temperature. After seven more washes, the reactions were developed with a 3-μg-e-phenylenediamine (OPD) tablet (Sigma) in 12 ml of substrate buffer and 0.05 M phosphate-citrate buffer followed by 12
Evaluation of tests and statistical analysis. In this study, there were more than 100 individuals in each subject group; therefore, we considered that the statistical data followed a normal distribution, regardless of the results of the normality test. The mean plus standard deviation (SD) of each group was used as the parameter, and values are expressed as the results of the normality test. The mean plus standard deviation (SD) of that the statistical data followed a normal distribution, regardless of the more than 100 individuals in each subject group; therefore, we considered

The reaction was stopped with 2 N sulfuric acid after 20 min of incubation in the dark. The optical density (OD) was measured at 490 nm (OD490) with an ELISA microplate reader (Molecular Devices, Sunnyvale, CA).

Evaluation of tests and statistical analysis. In this study, there were more than 100 individuals in each subject group; therefore, we considered that the statistical data followed a normal distribution, regardless of the results of the normality test. The mean plus standard deviation (SD) of each group was used as the parameter, and values are expressed as the results of the normality test. The mean plus standard deviation (SD) of each group was used as the parameter, and values are expressed as the mean OD ± SD. We used the means plus 2 SD of control subjects as cutoff values for distinguishing between a positive and negative result. For assessment of the significance of differences among the four groups, mean differences were evaluated by a receiver operator characteristic (ROC) curve analysis and Tukey’s multiple-comparison one-way analysis of variance (ANOVA). Differences in the median ODs of sera in the MAC-PD and LTBI subgroups were evaluated by the nonparametric Mann-Whitney test. Most statistical analyses were performed using Prism software, version 4.03 (GraphPad Software, San Diego, CA).

RESULTS

Identification of the MAV2054 and MAV5183 proteins. It is important to identify and test serologically active mycobacterial antigens to determine the most appropriate mixture of antigens for serodiagnosis. Therefore, we conducted broad-scale fractionation of CFP of M. avium and determined seroreactivity by ELISA. The CFP was fractionated by a sequential multistep chromatographic process that included hydrophobic interaction, hydroxyapatite, and ion exchange. IgG titers against MAV2054 and MAV5183 without the signal peptide (47 amino acids) was purified by Ni-NTA affinity chromatography. Due to the presence of a signal sequence at the N terminus of MAV5183, recombinant MAV5183 without the signal peptide (47 amino acids) was produced. The purity of both recombinant proteins was confirmed by SDS-PAGE (Fig. 2).

Overall seroreactive patterns of the four proteins. To investigate the serodiagnostic potential of the newly identified MAC proteins, serum IgG levels against each protein were measured in patients with MAC-PD, pulmonary TB, and LTBI and in HC. The HspX and 38-kDa antigen, well-known TB antigens that were prepared and described previously (13), were also included. As shown in Table 1 and in Fig. S1 in the supplemental material, all four antigens evoked significantly higher IgG responses in the MAC-PD and pulmonary TB groups than in the LTBI and HC groups. Among the antigens, MAV2054 elicited the highest antibody responses in pulmonary TB as well as MAC-PD patients. IgG titers against MAV2054 and MAV5183, but not HspX or 38-kDa antigen, were significantly different between the MAC-PD and pulmonary TB groups. However, MAC-PD and pulmonary TB patients reacted with both the TB and MAC antigens to consider.

Considering the mean plus 2 SD of HC as a cutoff value and a specificity of 94 to 97% for all antigens, MAV2054 showed the highest sensitivity for diagnosis of MAC-PD. Sensitivity of MAV2054 and the 38-kDa antigen for pulmonary TB was higher than that of the other two antigens. In general, the sensitivity of all antigens for diagnosis of MAC-PD was higher than that for pulmonary TB. MAV2054 for MAC-PD and 38-kDa antigen for pulmonary TB showed the highest areas under the concentration-time curve, respectively, compared to the other antigens.
together, these results suggest that the best candidates for the diagnosis of MAC-PD and active TB are MAV2054 and the 38-kDa antigen, respectively.

**Antibody responses according to TST or IGRA results.** There were no significant differences between HspX, the 38-kDa antigen, and MAV5183 in the LTBI (tuberculin reactor) and HC (tuberculin nonreactor) group results. However, it is possible that MAC-PD patients recognized the TB antigens due to coinfection with *M. tuberculosis*. To determine this, TST and IGRA were performed in suspect MAC-PD cases. A subset of the MAC-PD patients was classified into two groups on the basis of their TST or IGRA positivity. As shown in Table 2, no significant differences were observed in the IgG responses to any antigen between the TST+ or IGRA-positive and TST− or IGRA-negative groups. These results suggest that cross-reactivity to the four antigens between MAC-PD and TB patients may be due to the similarity of serum reactive epitopes among the antigens, rather than coinfection.

In this study, discrimination of the LTBI and HC groups was based on TST results. In addition, IGRA was performed in some subjects with LTBI; these were divided into IGRA-positive and -negative groups for comparison of their antibody responses. Interestingly, the median antibody level of the IGRA-positive group was higher than that of the IGRA-negative group (see Table S1 in the supplemental material). In particular, significant differences in IgG titers against MAV2054 and HspX between the IGRA-positive and -negative groups were observed. Additionally, the sensitivities of all antigens in the IGRA-positive group were significantly higher than in the IGRA-negative group.

**Antibody responses among MAC-PD subgroups.** The 175 MAC-PD patients were divided into two subgroups according to the presence of disease-causing bacteria, *M. avium* (48%; *n* = 84) and *M. intracellulare* (52%; *n* = 91). As shown in Table 3, levels of IgG for all antigens in the *M. intracellulare* group were higher than those in the *M. avium* group. In particular, significant differences in IgG titers against MAV5183 and the 38-kDa antigen between the groups were observed. Furthermore, the sensitivity of MAV5183 and the 38-kDa antigen for the *M. intracellulare* group was higher than that for the *M. avium* group.

The 89 MAC-PD patients for whom detailed radiographic information was available were classified into two subgroups: those with the nodular bronchiectatic form of the disease and those with the fibrocavitary form. Interestingly, the median antibody levels against MAV2054, MAV5183, and the 38-kDa antigen of the fibrocavitary form were statistically higher than those of the nodular bronchiectatic form.
brochiectatic and fibrocavitary data) represent significant differences according to a Mann-Whitney test that compared two unpaired groups (P < 0.05).

**TABLE 3** Comparison of IgG responses to mycobacterial antigens according to MAC-PD type

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Pathogen of MAC-PD</th>
<th>Median titer (IQR)</th>
<th>% sensitivity (no. of positive samples)</th>
<th>Radiographic findings of MAC-PD</th>
<th>Median titer (IQR)</th>
<th>% sensitivity (no. of positive samples)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAV2054</td>
<td>M. avium (n = 84)</td>
<td>0.459 (0.20–0.65)</td>
<td>51.2 (43)</td>
<td>Nodular bronchiectasis (n = 69)</td>
<td>0.389 (0.22–0.54)</td>
<td>40.6 (28)</td>
</tr>
<tr>
<td>MAV5183</td>
<td>M. intracellulare (n = 91)</td>
<td>0.251 (0.15–0.44)</td>
<td>36.9 (31)</td>
<td>Fibrocavitary (n = 20)</td>
<td>0.489 (0.28–0.68)</td>
<td>60.0 (12)</td>
</tr>
<tr>
<td>HspX</td>
<td></td>
<td>0.233 (0.14–0.37)</td>
<td>31.0 (26)</td>
<td></td>
<td>0.208 (0.14–0.30)</td>
<td>23.2 (16)</td>
</tr>
<tr>
<td>38-kDa</td>
<td></td>
<td>0.100 (0.06–0.15)</td>
<td>26.2 (22)</td>
<td></td>
<td>0.107 (0.07–0.17)</td>
<td>34.8 (24)</td>
</tr>
</tbody>
</table>

* Values indicated by superscript roman letters (“a” and “b” for comparisons between M. avium and M. intracellulare data and “c” and “d” for comparisons between nodular bronchiectasis and fibrocavitary data) represent significant differences according to a Mann-Whitney test that compared two unpaired groups (P < 0.05).

**DISCUSSION**

The rates of recovery of NTM from AFB smear-positive clinical specimens have increased worldwide, and NTM is responsible for an increasing proportion of mycobacterial disease in many developed countries (21, 22). When NTM are cultured and identified in respiratory specimens, a diagnosis of NTM lung disease requires differentiation between contamination and colonization (23). Thus, serological reactivity facilitates the diagnosis of such diseases. Differentiation of NTM lung disease from pulmonary TB is important to the clinician. MAC is the most common cause of NTM lung disease in many regions of the world. Although extensive studies to identify protein antigens suitable for serodiagnosis of TB have been performed, little effort has focused on identification and evaluation of protein antigens for diagnosis of NTM lung disease. Here we evaluated serologic responses to newly identified M. avium proteins (MAV2054 and MAV5183) and well-known M. tuberculosis proteins (HspX and the 38-kDa protein) in patients with MAC-PD or pulmonary TB and in HC. Interestingly, the newly identified MAV2054 elicited the highest antibody responses in both TB and MAC-PD patients.

The HspX and 38-kDa proteins reacted with sera from MAC-PD to levels similar to their reactivities with sera from active TB patients. One possible explanation for this apparent cross-

**TABLE 4** Effects of antigen combinations on sensitivity

<table>
<thead>
<tr>
<th>Antigen(s)</th>
<th>MAC-PD (n = 175)</th>
<th>Pulmonary TB (n = 123)</th>
<th>LTBI (n = 151)</th>
<th>% specificity (no. of positive sera) for HC (n = 141)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HspX</td>
<td>35.4 (62)</td>
<td>24.4 (30)</td>
<td>5.3 (8)</td>
<td>94.3 (8)</td>
</tr>
<tr>
<td>38-kDa</td>
<td>44.6 (78)</td>
<td>35.8 (44)</td>
<td>10.6 (16)</td>
<td>95.0 (7)</td>
</tr>
<tr>
<td>MAV2054</td>
<td>52.0 (91)</td>
<td>35.8 (44)</td>
<td>13.2 (20)</td>
<td>96.5 (5)</td>
</tr>
<tr>
<td>MAV5183</td>
<td>44.0 (77)</td>
<td>24.4 (30)</td>
<td>5.3 (8)</td>
<td>95.7 (6)</td>
</tr>
<tr>
<td>38-kDa + HspX</td>
<td>57.1 (100)</td>
<td>48.8 (60)</td>
<td>15.2 (23)</td>
<td>89.4 (15)</td>
</tr>
<tr>
<td>38-kDa + MAV5183</td>
<td>61.7 (108)</td>
<td>45.5 (56)</td>
<td>15.2 (23)</td>
<td>90.8 (13)</td>
</tr>
<tr>
<td>38-kDa + MAV2054</td>
<td>67.4 (118)</td>
<td>56.9 (70)</td>
<td>21.9 (33)</td>
<td>91.5 (12)</td>
</tr>
<tr>
<td>MAV2054 + MAV5183</td>
<td>62.9 (110)</td>
<td>46.3 (57)</td>
<td>15.2 (23)</td>
<td>92.2 (11)</td>
</tr>
<tr>
<td>MAV2054 + MAV5183 + HspX</td>
<td>66.3 (116)</td>
<td>51.2 (63)</td>
<td>17.9 (27)</td>
<td>87.9 (17)</td>
</tr>
<tr>
<td>38-kDa + HspX + MAV5183</td>
<td>68.6 (120)</td>
<td>56.1 (69)</td>
<td>18.5 (28)</td>
<td>85.1 (21)</td>
</tr>
<tr>
<td>38-kDa + HspX + MAV2054</td>
<td>71.4 (125)</td>
<td>59.3 (73)</td>
<td>24.5 (37)</td>
<td>87.2 (18)</td>
</tr>
<tr>
<td>38-kDa + MAV2054 + MAV5183</td>
<td>74.3 (130)</td>
<td>61.8 (76)</td>
<td>23.8 (36)</td>
<td>87.2 (18)</td>
</tr>
<tr>
<td>38-kDa + HspX + MAV2054 + MAV5183</td>
<td>76.0 (133)</td>
<td>65.0 (80)</td>
<td>26.5 (40)</td>
<td>83.0 (24)</td>
</tr>
</tbody>
</table>
reactivity is *M. tuberculosis* coinfection in MAC-PD patients. However, there was no significant difference in antibody responses to any antigen tested in TST-positive and -negative MAC-PD patients. MAC contains phosphate-binding protein, which is similar to the 38-kDa protein (PstS1) of *M. tuberculosis*, and alpha crystallin family protein, which is similar to HspX (Rv2031c, alpha crystallin). Our results suggest that epitopes contained in both proteins may also be present in MAC proteins. Therefore, when TB is diagnosed serologically using *M. tuberculosis* proteins, it is possible that the presence of MAC-PD may lead to false-positive results.

The newly identified MAV2054 and MAV5183 proteins elicited significantly higher antibody responses in the MAC-PD group than in those with pulmonary TB. However, considerable reactivity against both antigens in active TB was also observed. On an amino acid level, MAV2054 shares 100% homology with 35-kDa major membrane protein 1 (MMP-1) of *M. avium* subsp. *paratuberculosis* (MAP) and shows 92% identity and 97% positivity with respect to the MMP of *M. leprae*. MMP-1, which was originally discovered in *M. leprae* as a 35-kDa immunodominant protein (24), is a serodiagnostic antigen that elicits strong humoral immune responses in tuberculoid leprosy (25–27). In addition, the gene that encodes this protein is present in *M. abscessus* and *M. massiliense*; however, it is absent from other mycobacteria such as *M. tuberculosis* and *M. bovis* bacillus Calmette-Guérin (BCG) (27, 28). The MAV5183 gene encodes antigen 85C (Ag85C), which consists of the antigen 85 complex of *M. tuberculosis* (29). Ag85C was reported as a seroreactive protein in TB (30, 31) and is highly conserved among most mycobacteria except several species of NTM such as *M. fortuitum* or *M. chelonae*. In addition, MAV5183 had 85% amino acid sequence identity and 93% homology with *M. tuberculosis*. Therefore, seroreactivity against MAV2054 and MAV5183 in TB patients may due to the presence of similar epitopes in the various *M. tuberculosis* proteins or due to frequent exposure to MAC, which is ubiquitous in nature.

GPL is used extensively as an antigen for serodiagnosis of MAC-PD and differential diagnosis from pulmonary TB (7–9). GPLs are major components of the outer layer of many NTM cell envelopes and are serotype specific. In addition, GPLs are not present in the *M. tuberculosis* complex (32). Therefore, a combination multiple-lipid antigen ELISA that includes GPL (7) and an enzyme immunoassay (ELA) kit detecting serum IgA antibody specific for GPL core (8) were useful for diagnosis of MAC-PD and for differentiating MAC-PD from pulmonary TB. However, 24.8% of TB patients and only 4.2% of HC subjects were anti-GPL IgG positive (7). Those data and our results suggest that cross-reactivity might not be fully explicable by exposure or MAC coinfection in TB patients.

MAC lung disease has been classified as two distinct subtypes, the fibrocavitary and the nodular bronchiectatic forms. The fibrocavitary form is usually seen in middle-aged or elderly male alcoholics and/or smokers with coexistent chronic obstructive pulmonary disease (33). Chest radiography frequently demonstrates apical cavity changes, similar to those in reactivated TB. This form is generally progressive, and if left untreated can lead to extensive lung destruction and/or death. The nodular bronchiectatic form occurs predominantly in nonsmoking middle-aged or elderly females without previous or underlying lung disease (4, 34). In the present study, of 175 MAC-PD patients, 69 were classified as having the nodular bronchiectatic form and 20 the fibrocavitary form according to radiographic findings. Interestingly, fibrocavitary-form patients showed significantly higher antibody responses to three antigens than did those with the nodular bronchiectatic form, and these antigens showed a greater sensitivity for patients with the fibrocavitary form. The cavity form is generally progressive and has a higher burden of bacteria than the nodular bronchiectatic form (33). Therefore, cavitary disease with more-severe manifestations may elicit strong antibody responses to antigen. However, Kitada et al. (8) reported significantly higher antibody levels to GPL in nodular bronchiectatic-form than in fibrocavitary-form patients. To explain this discrepancy between antibody responses in the two forms of MAC-PD, further multivariate analysis using more clinical cases is necessary.

The two MAC species, *M. avium* and *M. intracellulare*, are the most frequently encountered causes of NTM pulmonary disease. In fact, they are isolated equally frequently from MAC lung patients (34). Although these species are distinct and can be identified and distinguished using nucleic acid probes, they are phenotypically very similar. Moreover, demographic and radiographic data and responses to therapy are indistinguishable between patients infected with these two species (33). Considering these clinical similarities, the other interesting finding of our study was that the antibody titers to four antigens in the *M. intracellulare* group were higher than those in the *M. avium* group. Recently, it was reported that patients with *M. intracellulare* lung disease exhibited a more severe presentation than patients with *M. avium* lung disease (35). Therefore, patients with *M. intracellulare* PD are presumed to have extensive lung lesions, which is consistent with the higher antibody responses in the *M. intracellulare* group.

It is generally accepted that multiple-antigen ELISAs can overcome the low sensitivity of TB serodiagnosis that results from individual heterogeneity in antibody responses. Rates of positivity for two or more antigens within the same assay were 52%, 32.5%, and 5.3% in MAC-PD, pulmonary TB, and HC subjects, respectively. Rates of positivity for three antigens were 32% and 17.1% in MAC-PD and active TB subjects, respectively. HC subjects did not react in assays that included three antigens. Finally, positivity rates with at least one antigen were 65% and 76% of active TB and MAC-PD subjects, respectively, with a specificity of 83%. These results suggest that subjects who showed positivity for two or more antigens were more likely to have MAC-PD or active TB. Recently, NTM have been responsible for an increasing proportion of mycobacterial lung disease in many developed countries and MAC has been the most common cause of NTM lung disease. Therefore, a cost-effective method for screening of mycobacterial lung disease, including pulmonary TB and MAC-PD, is required. Our findings suggest that an ELISA using the four antigens would be helpful for screening for this disease, although further confirmation is needed to discriminate the disease-causing pathogens. Further investigation on serological reactivity against the two MAV antigens in the patients with other NTM lung disease such as *M. kansasii* is needed to develop a more reliable screening method.

In conclusion, this is the first study to demonstrate the potential of MAV2054 and MAV5183 proteins as components of a serological test for the diagnosis of TB as well as MAC-PD. Although TB antibody detection is not recommended for the diagnosis of TB by the World Health Organization, it retains clinical value for auxiliary diagnosis and is widely used in countries with a high prevalence of TB. Therefore, multiple-antigen ELISAs that include MAV2054 and MAV5183 may facilitate diagnosis of MAC-
PD, in particular for smear- and culture-negative or culture- or PCR-negative cases.

ACKNOWLEDGMENTS

This research was supported by a fund (2011-E46002-00) by Research of Korea Centers for Disease Control and Prevention and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2012-2005763).

REFERENCES